Combined therapy of prednisone and mammalian target of rapamycin (mTOR) inhibitor sirolimus for treating retroperitoneal fibrosis
An erratum to this article was published (Ann Rheum Dis, Oct 2023 ↗)
Authors' conclusion
Our combined therapy resulted in significant fibrosis remission and an overall regression of the immune system towards healthy states, while achieving good tolerance.
Study context
- Population
- Patients with retroperitoneal fibrosis (RPF)
- Participants
- 8 patients
- Outcome
- Fibrous tissue mass (CT), inflammation markers and kidney function with combined prednisone + sirolimus
- Follow-up
- 48 weeks
Main finding
As reported in the abstract
Markers of acute inflammation reduced
70%
Further findings
Immune profiles
- Fibrosis-related T cell subsets (TH2, TH17, circulating TFH) reduced
- TNF and related cytokines restored to healthy levels
Original publication
Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis. Published 31 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →